Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

DIAGNOS

DB:4D4A
Snowflake Description

Worrying balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
4D4A
DB
CA$13M
Market Cap
  1. Home
  2. DE
  3. Healthcare
Company description

DIAGNOS Inc. provides software-based interpretation services in Canada, the United States, Kenya, the United Arab Emirates, Saudi Arabia, Mexico, and internationally. The last earnings update was 33 days ago. More info.


Add to Portfolio Compare Print
  • DIAGNOS has significant price volatility in the past 3 months.
4D4A Share Price and Events
7 Day Returns
-15.2%
DB:4D4A
4.1%
DE Healthcare Services
7.3%
DE Market
1 Year Returns
-3.6%
DB:4D4A
0.9%
DE Healthcare Services
-17.7%
DE Market
4D4A Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
DIAGNOS (4D4A) -15.2% 35% 5% -3.6% -89% -74.8%
DE Healthcare Services 4.1% -8.3% -18.1% 0.9% 24.9% 85.3%
DE Market 7.3% -17.9% -25.8% -17.7% -25.6% -29%
1 Year Return vs Industry and Market
  • 4D4A underperformed the Healthcare Services industry which returned 0.9% over the past year.
  • 4D4A outperformed the Market in Germany which returned -17.7% over the past year.
Price Volatility
4D4A
Industry
5yr Volatility vs Market

Value

 Is DIAGNOS undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether DIAGNOS is trading at an attractive price based on the cash flow it is expected to produce in the future. But as DIAGNOS has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for DIAGNOS. This is due to cash flow or dividend data being unavailable. The share price is €0.106.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for DIAGNOS's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are DIAGNOS's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:4D4A PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in CAD CA$-0.08
TSXV:ADK Share Price ** TSXV (2020-03-30) in CAD CA$0.19
Germany Healthcare Services Industry PE Ratio Median Figure of 6 Publicly-Listed Healthcare Services Companies 11.1x
Germany Market PE Ratio Median Figure of 400 Publicly-Listed Companies 16.36x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of DIAGNOS.

DB:4D4A PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= TSXV:ADK Share Price ÷ EPS (both in CAD)

= 0.19 ÷ -0.08

-2.24x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • DIAGNOS is loss making, we can't compare its value to the DE Healthcare Services industry average.
  • DIAGNOS is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does DIAGNOS's expected growth come at a high price?
Raw Data
DB:4D4A PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -2.24x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Europe Healthcare Services Industry PEG Ratio Median Figure of 14 Publicly-Listed Healthcare Services Companies 2.29x
Germany Market PEG Ratio Median Figure of 254 Publicly-Listed Companies 1.2x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for DIAGNOS, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on DIAGNOS's assets?
Raw Data
DB:4D4A PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in CAD CA$-0.01
TSXV:ADK Share Price * TSXV (2020-03-30) in CAD CA$0.19
Germany Healthcare Services Industry PB Ratio Median Figure of 7 Publicly-Listed Healthcare Services Companies 2.88x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.43x
DB:4D4A PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= TSXV:ADK Share Price ÷ Book Value per Share (both in CAD)

= 0.19 ÷ -0.01

-21.91x

* Primary Listing of DIAGNOS.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • DIAGNOS has negative assets, we can't compare the value of its assets to the DE Healthcare Services industry average.

Next steps:

  1. Take a look at our analysis of 4D4A’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through DIAGNOS's regulatory filings and announcements.
  3. Show me more potentially undervalued companies in the Healthcare Services industry
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess DIAGNOS's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Healthcare Services industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Healthcare Services industry average (and greater than 0)? (1 check)
  5. DIAGNOS has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is DIAGNOS expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as DIAGNOS has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
28.6%
Expected Healthcare Services industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is DIAGNOS expected to grow at an attractive rate?
  • Unable to compare DIAGNOS's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare DIAGNOS's earnings growth to the Germany market average as no estimate data is available.
  • Unable to compare DIAGNOS's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:4D4A Future Growth Rates Data Sources
Data Point Source Value (per year)
Europe Healthcare Services Industry Earnings Growth Rate Market Cap Weighted Average 28.6%
Europe Healthcare Services Industry Revenue Growth Rate Market Cap Weighted Average 8.5%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.3%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.1%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:4D4A Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in CAD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:4D4A Past Financials Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income *
2019-12-31 0 -2 -3
2019-09-30 0 -2 -3
2019-06-30 0 -3 -4
2019-03-31 0 -2 -4
2018-12-31 0 -3 -4
2018-09-30 1 -2 -4
2018-06-30 1 -1 -3
2018-03-31 1 -2 -4
2017-12-31 2 -2 -4
2017-09-30 2 -2 -3
2017-06-30 2 -2 -4
2017-03-31 2 -2 -3

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if DIAGNOS is high growth as no earnings estimate data is available.
  • Unable to determine if DIAGNOS is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:4D4A Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from DIAGNOS Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:4D4A Past Financials Data
Date (Data in CAD Millions) EPS *
2019-12-31 -0.08
2019-09-30 -0.12
2019-06-30 -0.18
2019-03-31 -0.20
2018-12-31 -0.23
2018-09-30 -0.21
2018-06-30 -0.20
2018-03-31 -0.22
2017-12-31 -0.25
2017-09-30 -0.23
2017-06-30 -0.27
2017-03-31 -0.24

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if DIAGNOS will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Take a look at our analysis of 4D4A’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. DIAGNOS's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Healthcare companies here
  3. DIAGNOS's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess DIAGNOS's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Europe market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Europe market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
DIAGNOS has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has DIAGNOS performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare DIAGNOS's growth in the last year to its industry (Healthcare Services).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • DIAGNOS does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare DIAGNOS's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare DIAGNOS's 1-year growth to the DE Healthcare Services industry average as it is not currently profitable.
Earnings and Revenue History
DIAGNOS's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from DIAGNOS Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:4D4A Past Revenue, Cash Flow and Net Income Data
Date (Data in CAD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 0.34 -2.87 1.83
2019-09-30 0.35 -3.33 1.97
2019-06-30 0.31 -3.89 2.14
2019-03-31 0.33 -3.84 2.17
2018-12-31 0.30 -4.13 2.11
2018-09-30 1.14 -3.64 2.40
2018-06-30 1.37 -3.38 2.34
2018-03-31 1.29 -3.77 2.71
2017-12-31 1.55 -4.02 3.09
2017-09-30 1.91 -3.41 2.93
2017-06-30 1.72 -3.69 3.17
2017-03-31 1.80 -2.94 2.58
2016-12-31 1.37 -2.29 2.06
2016-09-30 0.43 -3.07 1.97
2016-06-30 0.58 -2.95 2.05
2016-03-31 0.63 -3.04 2.33
2015-12-31 0.87 -3.09 2.57
2015-09-30 0.71 -3.04 2.49
2015-06-30 0.60 -2.84 2.22
2015-03-31 0.56 -2.83 2.13
2014-12-31 0.58 -2.69 2.07
2014-09-30 0.84 -2.47 2.09
2014-06-30 2.23 -1.88 2.02
2014-03-31 2.70 -1.64 2.11
2013-12-31 3.12 -1.29 2.22
2013-09-30 2.90 -1.46 2.42 -0.29
2013-06-30 1.60 -1.83 2.46 -0.15
2013-03-31 1.51 -2.04 2.55

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if DIAGNOS has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if DIAGNOS has efficiently used its assets last year compared to the DE Healthcare Services industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if DIAGNOS improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to its liabilities exceeding its assets.
X
Past performance checks
We assess DIAGNOS's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Healthcare Services industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
DIAGNOS has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is DIAGNOS's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up DIAGNOS's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • DIAGNOS's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • DIAGNOS's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of DIAGNOS's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • DIAGNOS has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from DIAGNOS Company Filings, last reported 2 months ago.

DB:4D4A Past Debt and Equity Data
Date (Data in CAD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 -0.37 0.69 0.31
2019-09-30 0.04 0.38 0.45
2019-06-30 0.00 0.16 0.05
2019-03-31 -5.08 5.45 0.65
2018-12-31 -4.35 5.41 1.17
2018-09-30 -5.30 5.27 0.05
2018-06-30 -4.57 4.57 0.21
2018-03-31 -3.64 4.47 0.16
2017-12-31 -2.38 4.44 1.36
2017-09-30 -2.34 3.57 0.28
2017-06-30 -1.52 3.60 1.14
2017-03-31 -2.91 3.24 0.20
2016-12-31 -2.71 3.70 0.89
2016-09-30 -3.46 4.31 0.90
2016-06-30 -3.56 4.05 0.18
2016-03-31 -2.60 3.43 0.49
2015-12-31 -1.98 2.86 0.51
2015-09-30 -1.26 2.73 1.27
2015-06-30 -0.87 1.23 0.25
2015-03-31 -0.22 0.94 0.40
2014-12-31 0.44 0.94 0.82
2014-09-30 1.11 0.92 1.42
2014-06-30 -0.30 0.89 0.25
2014-03-31 0.35 0.63 0.93
2013-12-31 0.77 0.00 0.66
2013-09-30 1.13 0.00 0.47
2013-06-30 1.28 0.00 0.55
2013-03-31 1.75 0.00 1.35
  • DIAGNOS has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if DIAGNOS's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • DIAGNOS has less than a year of cash runway based on current free cash flow.
  • DIAGNOS has less than a year of cash runway if free cash flow continues to grow at historical rates of 4.1% each year.
X
Financial health checks
We assess DIAGNOS's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. DIAGNOS has a total score of 1/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is DIAGNOS's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from DIAGNOS dividends.
If you bought €2,000 of DIAGNOS shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate DIAGNOS's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate DIAGNOS's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:4D4A Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Europe Healthcare Services Industry Average Dividend Yield Market Cap Weighted Average of 11 Stocks 1.7%
Germany Market Average Dividend Yield Market Cap Weighted Average of 323 Stocks 3.9%
Germany Minimum Threshold Dividend Yield 10th Percentile 1%
Germany Bottom 25% Dividend Yield 25th Percentile 1.7%
Germany Top 25% Dividend Yield 75th Percentile 5%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as DIAGNOS has not reported any payouts.
  • Unable to verify if DIAGNOS's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of DIAGNOS's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as DIAGNOS has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess DIAGNOS's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can DIAGNOS afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. DIAGNOS has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of DIAGNOS's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
André Larente
COMPENSATION CA$272,279
TENURE AS CEO 15.8 years
CEO Bio

Mr. André Larente has been the Chief Executive Officer and President of Diagnos Inc. since June 22, 2004. Mr. Larente has been a Director at Windfall Geotek Inc. (Formerly, Albert Mining Inc.) since May 31, 2017. Mr. Larente has been an Executive Director of Diagnos Inc. since September 21, 2000 and served as its acting Chief Financial Officer. Mr. Laurent served as the Chief Executive Officer and President of Diagnos from September 2000 to January 2003 and served as its Acting Chief Financial Officer. He was involved in the high-technology industry since 1978. He has been in the Information Technology Sector for more than 26 years. He held leading management positions at Companies such as Siemens, Syscan International, Newbridge Networks, Legent, Cognos, Tandem Computers and Honeywell Information Systems. Mr. Laurent has extensive informatics, software and engineering expertise, including leadership roles as General Manager of Siemens, Area Vice President of Newbridge Networks, Vice President of Legent Corporation, Director of Sales-Eastern Canada at Cognos Corporation, as well as 12 years at Honeywell in various sales positions. Mr. Larente has built several AI based applications at Diagnos such as: Computer based analysis of amateur composers’ songs, a FOREX application covering eight currencies, a Computer Assisted Resource Detection System for the natural resource sector and Computer Assisted Retina Analysis system. He served as the Chairman of Diagnos Inc. until July 24, 2009. He has been a Director of Majescor Resources Inc. since May 2015. He served as an Independent Director of Lucky Minerals Inc. since 2008. Mr. Laurent is a Graduate of Sherbrooke University and holds a Bachelor of Commerce and Management Information Systems Degree.

CEO Compensation
  • André's compensation has been consistent with company performance over the past year, both up more than 20%.
  • André's remuneration is lower than average for companies of similar size in Germany.
Management Team

André Larente

TITLE
CEO, President & Executive Director
COMPENSATION
CA$272K
TENURE
15.8 yrs

Marc-André Massue

TITLE
Chief Financial Officer
COMPENSATION
CA$172K
TENURE
11.8 yrs

Guillermo Robles

TITLE
Vice President of Sales
COMPENSATION
CA$160K

Hadi Chakor Djelthia

TITLE
Chief Medical Officer
Board of Directors Tenure

Average tenure and age of the DIAGNOS board of directors in years:

3.2
Average Tenure
61
Average Age
  • The tenure for the DIAGNOS board of directors is about average.
Board of Directors

François Côté

TITLE
Chairman of the Board
AGE
61
TENURE
0.5 yrs

André Larente

TITLE
CEO, President & Executive Director
COMPENSATION
CA$272K
TENURE
19.5 yrs

Georges Hébert

TITLE
Independent Director
COMPENSATION
CA$41K
AGE
71
TENURE
3.2 yrs

David Wong

TITLE
Member of the Scientific Advisory Board
TENURE
10.6 yrs

David LeBrun

TITLE
Member of the Scientific Advisory Board
TENURE
10.5 yrs

Reid Maclellan

TITLE
Independent Director
COMPENSATION
CA$29K
AGE
35
TENURE
1.9 yrs

Francis Bellido

TITLE
Director
TENURE
0.3 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by DIAGNOS individual insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
16. Mar 20 Buy Francis Bellido Individual 09. Mar 20 09. Mar 20 555,556 €0.12 €64,382
12. Mar 20 Buy Tristram Coffin Individual 09. Mar 20 09. Mar 20 783,334 €0.12 €90,779
12. Mar 20 Buy Georges Hébert Individual 09. Mar 20 09. Mar 20 277,778 €0.12 €32,191
14. Feb 20 Buy Tristram Coffin Individual 11. Feb 20 11. Feb 20 410,000 €0.12 €50,853
12. Dec 19 Buy Georges Hébert Individual 06. Dec 19 06. Dec 19 8,000 €0.10 €819
10. Dec 19 Buy Georges Hébert Individual 06. Dec 19 09. Dec 19 92,000 €0.10 €9,403
04. Dec 19 Buy André Larente Individual 04. Dec 19 04. Dec 19 124,851 €0.11 €13,298
X
Management checks
We assess DIAGNOS's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. DIAGNOS has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

DIAGNOS Inc. provides software-based interpretation services in Canada, the United States, Kenya, the United Arab Emirates, Saudi Arabia, Mexico, and internationally. It offers image analysis services through Computer Assisted Retinal Analysis, a software tool that assists health specialists in the detection of diabetic retinopathy. The company was founded in 1998 and is headquartered in Brossard, Canada.

Details
Name: DIAGNOS Inc.
4D4A
Exchange: DB
Founded: 1998
CA$8,064,373
61,366,004
Website: http://www.diagnos.ca
Address: DIAGNOS Inc.
7005 Taschereau Boulevard,
Suite 340,
Brossard,
Quebec, J4Z 1A7,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
TSXV ADK Common Shares TSX Venture Exchange CA CAD 30. Nov 2000
OTCPK DGNO.F Common Shares Pink Sheets LLC US USD 30. Nov 2000
DB 4D4A Common Shares Deutsche Boerse AG DE EUR 30. Nov 2000
Number of employees
Current staff
Staff numbers
0
DIAGNOS employees.
Industry
Health Care Technology
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/03/30 22:41
End of day share price update: 2020/03/30 00:00
Last earnings filing: 2020/02/26
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/03/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.